Program
isomyosamine
Its studies are mostly in Frailty, led by TNF Pharmaceuticals.
Furthest: phase 2, since Apr 9, 20251 company-led study, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| TNF Pharmaceuticals | 11 open or running | phase 2since Apr 9, 2025 | Apr 9, 2025 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 9, 2025First study: phase 2 study in FrailtyFirst studyNCT06942182 · 60 planned
TargetBeta
IL6 →read by rule
“Isomyosamine is a promising oral medication that reduces inflammation by targeting cytokines like TNF-α and IL-6, which are linked to these conditions.”study text, by rule · the study
Other programs on IL6
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| olokizumabrule | R-Pharm | phase 3 | 19 |
| ziltivekimabrule | Novo Nordisk | phase 3 | 12 |
| clazakizumab | CSL | phase 3 | 10 |
| pacibekitugrule | Novartis | phase 3 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06942182Frailty | 2 | Not yet recruiting | Mar 1, 2026 | 60 |
How it is read
Names in the registry
- “Isomyosamine 250mg”, 1 entry
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.